Registration now open for the webinar 𝘿𝙚𝙨𝙚𝙣𝙨𝙞𝙩𝙞𝙨𝙖𝙩𝙞𝙤𝙣 𝙎𝙩𝙧𝙖𝙩𝙚𝙜𝙞𝙚𝙨 on 𝗧𝘂𝗲𝘀𝗱𝗮𝘆, 𝟭 𝗠𝗮𝗿𝗰𝗵 𝗮𝘁 𝟭𝟴:𝟬𝟬 𝗖𝗘𝗧!
With Prof. Nizam Mamode & Prof. Christophe Legendre
This activity is sponsored by Hansa Biopharma
Register now!
Registration now open for the webinar 𝘿𝙚𝙨𝙚𝙣𝙨𝙞𝙩𝙞𝙨𝙖𝙩𝙞𝙤𝙣 𝙎𝙩𝙧𝙖𝙩𝙚𝙜𝙞𝙚𝙨 on 𝗧𝘂𝗲𝘀𝗱𝗮𝘆, 𝟭 𝗠𝗮𝗿𝗰𝗵 𝗮𝘁 𝟭𝟴:𝟬𝟬 𝗖𝗘𝗧!
With Prof. Nizam Mamode & Prof. Christophe Legendre
This activity is sponsored by Hansa Biopharma
Register now!
Following the TLJ 2.0 event last November, two important papers have been published in Transplant International focusing on the meeting’s Workstream 4: Normothermic regional perfusion (NRP) in donation after circulatory death (DCD). One paper concerns a systematic review and meta-analyses of NRP in DCD donation, with the other focuses on a consensus statement on the
A double appointment this week with the #ESOTchat on twitter at 21:00 CEST (for 30 minutes): Monday is #ESOTTLJ WS06 on recommendations concerning the management of the patient with HLA antibodies Wednesday is #ESOTcongress on people with transplants at the centre See you on Twitter!
Recommendations from Workstream 6 of the ESOT Transplantation Learning Journey (TLJ 2.0) project, concerning the management of the patient with HLA antibodies We are pleased to present the recommendations from Workstream 6 of the ESOT Transplantation Learning Journey (TLJ 2.0) project, concerning the management of the patient with HLA antibodies. Over recent months, our group
As part of the TLJ 2.0, Workstream 6 has been considering the management of patients with HLA antibodies, with the aim of publishing a clinical guideline. On 28 August a meeting will take place in Milan with experts in the field and the wider clinical community to discuss the latest draft, after which the guideline
An assessment of the impact of COVID-19 on transplantation practice, one year from the start of the pandemic.
A working group of European experts has summarised the current technique and logistical aspects as they are implemented in their countries and / or centres. From these discussions, and supported by literature, the TJL2.0 Work Stream has created a list of recommendations and minimal requirements any NRP programme should follow. We ask your help to
Transplant patients are exceptionally vulnerable to all infections, especially COVID-19, due to immunosuppression and other co-morbidities. There is a clear need for these patients to receive the best available protection against COVID-19 and we strongly believe that they should be considered as a priority group for vaccination across Europe. Furthermore, our patients and the broader
This pre-print from TLJ 2.0 WS03 on ‘Managing Immunosuppressant Therapy in Potentially Cured Post-Kidney Transplant Cancer’ is now open for comments on Transplant Live. Led by Umberto Maggiore, this paper will be submitted to Transplant International once feedback from our community has been collated. Login & provide your input today
We are pleased to announce that our TLJ 2.0 report has been published and is available to read now. Providing a comprehensive summary of TLJ 2.0, this report covers all the highlights from the event, including the key discussion points and outcomes from some of the World’s leading transplant experts. Read the TLJ20Report for the